Aurobindo Pharma Reports 6.3% Revenue Growth to ₹8,286 Crores in Q2

Aurobindo Pharma Limited, a leading pharmaceutical company, has announced its financial results for the second quarter, showcasing strong performance across key metrics.

Revenue and Profit Growth

For the quarter, Aurobindo Pharma reported consolidated revenue from operations of ₹8,286.00 crores, marking a 6.3% increase compared to the same period last year. The company's profit after tax reached ₹848.00 crores, up by 3.8% year-on-year.

Segment Performance

The company's performance was driven by growth across various geographical segments:

Segment	Revenue (₹ Crore)	YoY Growth
US Formulations	3,638.00	Not specified
Europe	2,480.00	17.8%

The US formulations business accounted for 43.9% of consolidated revenue. Europe showed growth of 17.8%, contributing significantly to the overall performance.

Operational Highlights

EBITDA grew 7.1% to ₹1,678.00 crores, with a margin of 20.3%.
R&D spending was ₹414.00 crores, representing 5% of revenues.
The company filed 13 ANDAs with US FDA during the quarter.
Received final approval for 7 ANDAs from the USFDA.
Launched 6 products during the quarter.

Financial Position

Aurobindo Pharma maintained a financial position with:

Net cash position of $170.00 million.
Free cash flow generation of $57.00 million during the quarter (before dividend and buybacks).

Biosimilars Progress

Three products including trastuzumab biosimilar were approved by European Commission.
Four biosimilar products including bevacizumab and trastuzumab biosimilars were approved by MHRA UK.

Aurobindo Pharma's Q2 results reflect its business model and focus on key markets. The company's continued investment in R&D and new product approvals may position it for future growth in the global pharmaceutical market.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.82%	+4.52%	+4.80%	-7.48%	-18.34%	+46.99%

Aurobindo Pharma Limited, a prominent player in the pharmaceutical industry, has recently disclosed significant changes in its senior management team. The company has announced the departure of two key executives, marking a shift in its leadership structure.

Senior Management Changes

Executive	Position	Nature of Departure	Effective Date
Dr. Mandepudi Sudhakara Reddy	Associate President, Corporate QA	Resignation	November 4, 2025
Mr. K.P. Ravinatha Shetty	President, Operations	Retirement (Superannuation)	November 3, 2025

Details of Departures

Dr. Mandepudi Sudhakara Reddy's Resignation

Dr. Mandepudi Sudhakara Reddy, who held the position of Associate President of Corporate QA, has decided to step down from his role. According to the company's disclosure:

Dr. Reddy submitted his resignation letter on August 9, 2025.
He cited acceptance of a new opportunity aligning with his career aspirations as the reason for his departure.
The company has accepted his resignation, and he will be relieved from his duties effective from the close of business hours on November 4, 2025.

Mr. K.P. Ravinatha Shetty's Retirement

Mr. K.P. Ravinatha Shetty, who served as the President of Operations, has retired from the company. The details of his retirement are as follows:

Mr. Shetty retired upon reaching superannuation on November 3, 2025.
He will be officially relieved from his services effective November 4, 2025.

Regulatory Compliance

Aurobindo Pharma Limited has made this disclosure in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided the necessary details as required by the regulatory framework, ensuring transparency in its corporate governance practices.

These changes in the senior management team may have implications for Aurobindo Pharma's operations and strategic direction.